Five notes:
1. The spine market continued to stabilize in the second quarter, with NuVasive building on its first-quarter net sales of $271.2 million.
“Our continued investments in the cervical and anterior procedural segments and our international commercial organization are advancing both our near- and long-term growth strategy,” CEO Chris Barry said in a July 28 news release.
2. Second-quarter growth was due to recovery from the pandemic “across all procedural segments and continued strong international growth,” the company said.
3. GAAP net income was $1.8 million in the second quarter, compared to a GAAP net loss of $50 million for the same period in 2020.
4. As of June 30, cash, cash equivalents and investments were $204.1 million.
5. NuVasive said it expects full-year net sales to be about $1.2 billion.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
